Comprehensive genomic analysis identifies MDM2 and AURKA as novel amplified genes in juvenile angiofibromas
✍ Scribed by Bernhard Schick; Silke Wemmert; Ulrike Bechtel; Piero Nicolai; Thiemo Hofmann; Wieslaw Golabek; Steffi Urbschat
- Book ID
- 102232521
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 181 KB
- Volume
- 29
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background.
Frequent β‐catenin mutations have been detected in juvenile angiofibromas, but the tumor pathogenesis remains unknown.
Methods.
Metaphase‐comparative genomic hybridization (CGH) was used to identify chromosomal aberrations in 29 tumor specimens. Two tumors were investigated using genome DNA microarrays.
Results.
Three hundred eleven chromosomal gains and losses were detected by metaphase‐CGH. Frequent chromosomal gains were detected at 4q, 6, 12, and X, while frequent chromosomal losses affected regions of chromosomes 8, 16, 17, 22, and Y. Genome DNA microarray analysis in 2 tumors of the series confirmed chromosomal aberrations, detected by metaphase‐CGH, and indicated genes such as AURKA (20q13.2) not being recognized by metaphase‐CGH.
Conclusion.
Metaphase‐CGH results confirmed numerous chromosomal aberrations in juvenile angiofibromas. The most frequent aberrations affected sex chromosomes. Further consensus regions of chromosomal aberrations were detected at 4q, 6, 8, 12, 16, 17, and 22. AURKA and MDM2 were identified as interesting novel amplified genes in juvenile angiofibromas. © 2006 Wiley Periodicals, Inc. Head Neck, 2007